Results 51 to 60 of about 16,340 (253)

Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study

JMIR Research Protocols, 2020
BackgroundRadioembolization, also known as transarterial radioembolization or selective internal radiation therapy with yttrium-90 (90Y) resin microspheres, is an established treatment modality for patients with primary and secondary liver tumors ...
Helmberger, Thomas, Arnold, Dirk, Bilbao, José I, de Jong, Niels, Maleux, Geert, Nordlund, Anders, Peynircioglu, Bora, Sangro, Bruno, Sharma, Ricky A, Walk, Agnes   +9 more
doaj   +1 more source

Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives [PDF]

, 2015
In the last decade trans-arterial radioembolization has given promising results in the treatment of patients with intermediate or advanced stage hepatocellular carcinoma (HCC), both in terms of disease control and tolerability profile.
Bargellini, Irene, Bartolozzi, Carlo, Bertini, Marco, Bresci, Giampaolo, Corti, Ambra, Federici, Graziana, Giacomelli, Luca, Giorgi, Luigi, Marceglia, Sara, Metrangolo, Salvatore, Mismas, Valeria, Parisi, Giuseppe, Piccinno, Michele, Romano, Antonio, Sacco, Rodolfo, Tredici, Manuel, Tumino, Emanuele   +16 more
core   +1 more source

Combining Immunotherapy with Transarterial Radioembolization

Indian Journal of Nuclear Medicine, 2023
Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy.
Balaban Genc, Zeynep Ceren, Soydemır, Efe, Ersoy, Seval Ay, Ones, Tunc   +3 more
openaire   +2 more sources

Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose?

Frontiers in Gastroenterology, 2023
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy and its incidence is rising in Western countries. Although surgical resection is considered the only curative treatment, up to 70% of patients are diagnosed at an ...
Maria Adriana Cocozza, Lorenzo Braccischi, Antonio De Cinque, Antonio Bruno, Alberta Cappelli, Matteo Renzulli, Antonello Basile, Massimo Venturini, Pierleone Lucatelli, Francesco Modestino, Cristina Mosconi   +10 more
doaj   +1 more source

Computational simulation of the predicted dosimetric impact of adjuvant yttrium-90 PET/CT-guided percutaneous ablation following radioembolization [PDF]

, 2016
Background: 90Y PET/CT post-radioembolization imaging has demonstrated that the distribution of 90Y in a tumor can be non-uniform. Using computational modeling, we predicted the dosimetric impact of post-treatment 90Y PET/CT-guided percutaneous ablation ...
Abigail Lin, Alexander S. Pasciak, Christos Georgiades, Laura K. Findeiss, Shannon Kauffman, Yong C. Bradley   +5 more
core   +2 more sources

Radioembolization for hepatocellular carcinoma

Journal of Hepatology, 2012
Radioembolization is a form of brachytherapy in which intra-arterially injected (90)Y-loaded microspheres serve as sources for internal radiation purposes. It produces average disease control rates above 80% and is usually very well tolerated. Main complications do not result from the microembolic effect, even in patients with portal vein occlusion ...
Sangro, Bruno, Iñarrairaegui, Mercedes, Bilbao, Jose I.   +2 more
openaire   +2 more sources

Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure

International Journal of Hyperthermia, 2022
The majority of patients with metastatic colorectal cancer (CRC) to the liver are not amenable to curative-intent surgery or thermal ablation; there is a need for alternative locoregional therapies to control oligometastatic liver disease.
Pouya Entezari, Ahmed Gabr, Riad Salem, Robert J. Lewandowski   +3 more
doaj   +1 more source

Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus [PDF]

, 2017
Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat inoperable primary or metastatic liver tumors.
Brown, DB, Fakih, M, Feilchenfeldt, J, Gibbs, P, Kennedy, A, Knuth, A, Marshall, J, Pittari, G, Sangro, B, Sharma, RA, Soulen, MC, Wasan, H   +11 more
core   +1 more source

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

The Oncologist
Background Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC).
Shawn Yu, Menggang Yu, Barry Keane, David M. Mauro, P. Helft, William Proctor Harris, H. Sanoff, Matthew S. Johnson, B. O'Neil, A. McRee, Ashwin S Somasundaram   +10 more
semanticscholar   +1 more source

Radioembolization for hepatocellular carcinoma: what clinicians need to know

Journal of Liver Cancer, 2022
Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea.
Jin Woo Choi, Hyo-Choel Kim
semanticscholar   +1 more source